Expert Interviews

New research led by Geetika Kennady, MD, FAAP, showed that 10.6% of newborns have iron deficiency, supporting a push for earlier screening.

"We've updated our internal clinical pathways to recommend 5 days for kids hospitalized with uncomplicated pneumonia," Cotter noted.

At PAS 2025, Jesse Hinckley, MD, PhD, presented data showing cannabis use sharply increases odds of depression and suicidal behavior in youth.

Jennifer Nestor, MD, evaluated a digital stethoscope to validate pediatric breath sound recordings for potential machine learning algorithm development.

Shorter antibiotic courses for AOM and CAP in children proved effective across a pediatric health system, according to data presented by Elysha Pifko, MD.

Joshua Feder, MD, emphasizes that sensory play is most effective when rooted in relational strategies that support autistic children in daily environments.

Recent research detailed that a child was most likely to be killed in a mass shooting by a parent or family member vs a stranger or peer. Study investigator Stephanie Chao, MD, breaks down these data.

Ambulatory blood pressure monitoring at point-of-care shows high feasibility for pediatric hypertension diagnosis in clinical practice.

Jay T. Rubinstein, MD, PhD, emphasized that children with hearing loss should receive genetic testing, as the investigational DB-OTO gene therapy demonstrated positive results.

Walker and Harris emphasize the importance of early hearing loss detection, screening, and intervention to support optimal child development.

Danielle Van Damme, DNP, CPNP-AC, discussed key updates from the 2024 IDSA guideline on diagnosing complicated intra-abdominal infections, emphasizing ultrasound as the preferred imaging modality.

Karen Y. Capusan, DNP, CPNP-PC, explored RSV’s shifting epidemiology, seasonal trends, and new vaccines’ role in reducing hospitalizations at the 2025 NAPNAP National Conference.

At the 2025 NAPNAP Conference in Chicago, Jessica Spruit, DNP, CPNP-AC, FAANP, discussed the AAP's first clinical practice guideline on opioid prescribing.

Bobbie Monaco, MSN, CPNP-PC, provided a recap of her NAPNAP session regarding period poverty, and called for continued advocacy and awareness in the United States and globally.

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, comments on the ongoing measles outbreaks and encourages advocation for vaccines and accurate information.

Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP, highlighted key updates on influenza, COVID-19, and RSV vaccines at the 2025 NAPNAP National Conference.

Tina Tan, MD, FIDSA, FPIDS, FAAP, comments on the FDA's recent selection of the 2025-2026 influenza vaccine compositions, without the CDC's ACIP meeting and FDA's VRBPAC meeting.

In the final part of this 5-part series, panelists discuss new allergy treatments such as Xolair, early immunotherapy, and their broader impact.

In part 4 of this 5-part series, panelists discuss gaps in pediatric food allergy care, stressing better diagnosis, education, and management.

In part 3 of this 5-part series, panelists discuss the recent Neffy approval, oral immunotherapy, and Xolair’s role in allergy management.

In part 2 of this 5-part series, panelists discuss confusion in food allergy diagnosis and the need for better medical education.

In part 1 of this 5-part series, panelists discuss early allergen introduction, oral immunotherapy, and Xolair for food allergy.

Mary Koslap-Petraco highlighted the need to address vaccine hesitancy, catch up on immunizations, and build trust with parents at the 2025 NAPNAP National Conference on Pediatric Health Care.

At the 2025 NAPNAP National Conference, Maureen Madden, DNP, CPNP-AC, CCRN, FCCM, FAAN, explained why the yearly conference is important for both providers and pediatric patients.

Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP, reacts to the recent cancelations of the ACIP and VRBPAC and comments on the potential down stream effects.

At the 2025 NAPNAP National Conference, Maureen Madden, DNP, CPNP-AC, CCRN, FCCM, FAAN, provides the key takeaways and recommendations for glycemic control guidance, updated in 2024.

Jay T. Rubinstein, MD, PhD, highlighted promising CHORD trial data showing that DB-OTO gene therapy has led to hearing improvements in treated participants.

Panelists discuss the current treatment landscape for atopic dermatitis, noting significant advances in biologics and systemic therapies, and share optimism about the future of management, highlighting ongoing research and the potential for more targeted, personalized treatments to improve patient outcomes.

"Vaccines are our absolute best defense for protecting people of all ages against many serious infectious diseases," Tan said in a statement as president of IDSA.

Panelists discuss offering guidance to parents and caregivers experiencing atopic dermatitis for the first time, emphasizing the importance of education on managing flare-ups, proper skin care routines, and setting realistic treatment expectations while also seeking support from health care professionals to navigate the challenges of the condition.